IceCure Medical has submitted a regulatory filing to China's National Medical Products Administration (NMPA) seeking the ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Per IceCure Medical, the FDA approval for the XSense Cryoablation System marks a significant step in the medical technology landscape.Following the FDA clearance, IceCure is likely to solidify its ...

The ProSense® Cryoablation System is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid ...

FDA Granted Regulatory Clearance for XSense™ Cryoablation System with CryoProbes: The next-generation XSense™ system is cleared for the same indications that our flagship ProSense® system is ...

Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

IceCure Medical (ICCM) has submitted a regulatory filing with China’s National Medical Products Administration for the approval of its ProSense ...

The abstract titled "Cryoablation as a primary treatment for ... the Japan Patent Office for its invention titled 'Cryogenic System with Multiple Submerged Pumps'. IceCure Medical Ltd. (Nasdaq ...

IceCure's IceSense3, its predecessor cryoablation system, already has regulatory approval in China. The indicated use for ProSense® in China, per the Company's regulatory filing application ...